These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22213866)

  • 1. [Long-term follow-up of malignant clonal evolution in patients with acquired aplastic anemia].
    Li XX; Ge ML; Shi J; Feng XY; Shao YQ; Qian LS; Zheng YZ
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):463-7. PubMed ID: 22213866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of clonal evolutions in 802 aplastic anemia patients: a single-center experience.
    Li Y; Li X; Ge M; Shi J; Qian L; Zheng Y; Wang J
    Ann Hematol; 2011 May; 90(5):529-37. PubMed ID: 21207031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The clinical significance of evolution of paroxysmal nocturnal haemoglobinuria clones in aplastic anemia patients].
    Li YM; Li XX; Ge ML; Shi J; Shao YQ; Qian LS; Zheng YZ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):117-22. PubMed ID: 22730662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Aplastic anemia with macrocytic anemia: a study based on long-term follow-up].
    Li YM; Li XX; Sun H; Sun L; Wan DM; Liu LX; Chen SM; Chen SQ; Liu SJ; Zheng YZ; Zou DB
    Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):117-21. PubMed ID: 23611217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party.
    Socié G; Henry-Amar M; Bacigalupo A; Hows J; Tichelli A; Ljungman P; McCann SR; Frickhofen N; Van't Veer-Korthof E; Gluckman E
    N Engl J Med; 1993 Oct; 329(16):1152-7. PubMed ID: 8377778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Acquired aplastic anemia developing myelodysplastic syndrome/acute myeloid leukemia: clinical analysis of nineteen patients and literatures review].
    Ma L; Li X; Zhang J; Shao Y; Nie N; Huang Z; Ge M; Zheng Y; Qu D; Shi J
    Zhonghua Xue Ye Xue Za Zhi; 2015 Mar; 36(3):216-20. PubMed ID: 25854465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience. German/Austrian Pediatric Aplastic Anemia Working Group.
    Führer M; Burdach S; Ebell W; Gadner H; Haas R; Harbott J; Janka-Schaub G; Klingebiel T; Kremens B; Niemeyer C; Rampf U; Reiter A; Ritter J; Schulz A; Walther U; Zeidler C; Bender-Götze C
    Klin Padiatr; 1998; 210(4):173-9. PubMed ID: 9743949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
    Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
    Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
    J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis.
    Forrest DL; Nevill TJ; Naiman SC; Le A; Brockington DA; Barnett MJ; Lavoie JC; Nantel SH; Song KW; Shepherd JD; Sutherland HJ; Toze CL; Davis JH; Hogge DE
    Bone Marrow Transplant; 2003 Nov; 32(9):915-23. PubMed ID: 14561993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
    Kröger N; Brand R; van Biezen A; Cahn JY; Slavin S; Blaise D; Sierra J; Zander A; Niederwieser D; de Witte T;
    Bone Marrow Transplant; 2006 Jan; 37(2):183-9. PubMed ID: 16299545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience.
    Aguilera DG; Vaklavas C; Tsimberidou AM; Wen S; Medeiros LJ; Corey SJ
    J Pediatr Hematol Oncol; 2009 Nov; 31(11):803-11. PubMed ID: 19801947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
    Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
    Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma.
    Howe R; Micallef IN; Inwards DJ; Ansell SM; Dewald GW; Dispenzieri A; Gastineau DA; Gertz MA; Geyer SM; Hanson CA; Lacy MQ; Tefferi A; Litzow MR
    Bone Marrow Transplant; 2003 Aug; 32(3):317-24. PubMed ID: 12858205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome in acquired aplastic anemia treated with an intensified dose schedule of horse antilymphocyte globulin in combination with androgens.
    Leleu X; Terriou L; Duhamel A; Moreau AS; Andrieux J; Dupire S; Coiteux V; Berthon C; Micol JB; Guieze R; Facon T; Bauters F
    Ann Hematol; 2006 Oct; 85(10):711-6. PubMed ID: 16830141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on the transformation from myelodysplastic syndromes into acute leukemias].
    Shi J; Shao Z; Liu H; Li K; Song L; Zhang Y; Zheng Y; Chen G; Chu Y; He H; Zhao M; He G; Feng B; Hao Y; Yang T; Yang C
    Zhonghua Xue Ye Xue Za Zhi; 2001 Jul; 22(7):351-4. PubMed ID: 11877096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children.
    Kojima S; Ohara A; Tsuchida M; Kudoh T; Hanada R; Okimoto Y; Kaneko T; Takano T; Ikuta K; Tsukimoto I;
    Blood; 2002 Aug; 100(3):786-90. PubMed ID: 12130487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.